Allurion TechnologiesALUR
About: Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 24
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
4.2% more ownership
Funds ownership: 21.7% [Q2] → 25.9% (+4.2%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1% less capital invested
Capital invested by funds: $10.3M [Q2] → $10.2M (-$110K) [Q3]
16% less funds holding
Funds holding: 32 [Q2] → 27 (-5) [Q3]
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
TD Cowen Joshua Jennings 56% 1-year accuracy 9 / 16 met price target | 385%upside $2 | Buy Initiated | 2 Oct 2024 |
Roth MKM Jason Wittes 31% 1-year accuracy 5 / 16 met price target | 385%upside $2 | Buy Initiated | 6 Sept 2024 |
Chardan Capital Keay Nakae 8% 1-year accuracy 2 / 24 met price target | 507%upside $2.50 | Buy Maintained | 22 Aug 2024 |
Financial journalist opinion
Based on 6 articles about ALUR published over the past 30 days
